Research Presentations Financial Disclosure Statements ISPOR 6th Asia-Pacific Conference Abstracts

Download Research Presentations Financial Disclosure Statements ISPOR 6th Asia-Pacific Conference Abstracts

Post on 07-Mar-2017

214 views

Category:

Documents

2 download

Embed Size (px)

TRANSCRIPT

  • DISCLOSURE INFORMATION

    Research Presentations Financial Disclosure Statements

    The International Society for Pharmacoeconomics and Outcomes Research asked all abstract contributors to disclose fi nancial support for their research. The following fi nancial support was declared:

    Copyright 2014, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

    REFERENCE CODE

    FINANCIAL SUPPORT

    CN1 NoneCN2 HIHR HTA, Southampton, UKCN3 Pfi zer (Thailand) Limited, Bangkok, ThailandCN4 NoneCV1 NoneCV2 NoneCV3 National Health Insurance Administration, Taiwan, Taipei, TaiwanCV4 NoneDB1 NoneDB2 Eli Lilly and Company, Indianapolis, IN, USADB3 NoneDB4 Pfi zer Inc., New York, NY, USADU1 Amgen, Thousand Oaks, CA, USADU2 NoneDU3 NoneDU4 NoneHC1 NoneHC2 Novartis Pharma AG, Basel, SwitzerlandHC3 Bristol-Myers Squibb, Mulgrave, AustraliaHC4 NoneHS1 NoneHS2 Kinapse Ltd., Wimbledon, EnglandHS3 China Health Insurance Research Association, Beijing, ChinaHS4 NoneIN1 The National Engineering Research Center Of Ultrasonic Medical

    Treatment, Chongqing, ChinaIN2 GlaxoSmithKline (China) Investment Co., Ltd., Beijing, ChinaIN3 MSD (Thailand) Ltd., Bangkok, ThailandIN4 NoneMH1 NoneMH2 NoneMH3 NoneMH4 NonePCN1 Faculty of Pharmaceutical Sciences, Chulalongkorn University,

    Bangkok, ThailandPCN2 American Cancer Society, Atlanta, GA, USAPCN3 NonePCN4 China Medical Board, Boston, MA, USAPCN5 GlaxoSmithKline, Wavre, BelgiumPCN6 Pfi zer, Inc., New York, NY, USAPCN7 Eli Lilly and Company, Indianapolis, IN, USAPCN8 Eli Lilly China, Shanghai, ChinaPCN9 NonePCN10 Karaganda State Medical University, Karaganda, KazakhstanPCN11 NonePCN12 Hungarian Academy of Sciences (HAS) Bolyai Jnos Research

    Fellowship, Budapest, Hungary; University of Pcs, Faculty of Health Sciences, Pcs, Hungary

    PCN13 NonePCN16 NonePCN17 NonePCN18 NonePCN19 Boehringer Ingelheim (Taiwan) Ltd., Taipei, TaiwanPCN20 Celgene South Korea, Seoul, South KoreaPCN21 NonePCN22 GE Medical Systems Trade Development (Shanghai) Co. Ltd.,

    Shanghai, ChinaPCN23 NonePCN24 Department of Health Philippines, Manila, Philippines; Rockefeller

    Foundation, New York, NY, USA; World Health Organization, Geneva, Switzerland; Health Intervention and Technology Assessment Program, Nonthaburi, Thailand; National Institute for Health and Care Excellence International, London, UK

    PCN25 NonePCN26 MSD (Thailand) Ltd., Bangkok, ThailandPCN27 NonePCN28 Celgene, Summit, NJ, USAPCN29 NonePCN31 Pfi zer (Thailand) Ltd., Bangkok, ThailandPCN32 NonePCN33 NonePCN34 NonePCN35 National Medical Research Council, Singapore, SingaporePCN36 NonePCN37 None

    REFERENCE CODE

    FINANCIAL SUPPORT

    PCN38 SMs Consulting, Ltd., Bratislava, Slovak RepublicPCN39 NonePCN40 Faculty of Pharmaceutical Sciences, Chulalongkorn University,

    Bangkok, ThailandPCN41 Decision Resources Group, Burlington, MA, USAPCN42 Maharishi Markandeshwar University, Ambala Haryana, IndiaPCN44 NonePCN45 NonePCN46 Bristol-Myers Squibb, Taipei, TaiwanPCN47 NonePCN48 Hungarian Academy of Sciences (HAS) Bolyai Jnos Research

    Fellowship, Budapest, Hungary; University of Pcs, Faculty of Health Sciences, Pcs, Hungary

    PCV1 NonePCV2 NonePCV4 Pfi zer, Inc., New York, NY, USAPCV5 Eli Lilly and Company, Indianapolis, IN, USAPCV6 Pfi zer Inc., New York, NY, USAPCV7 HSUM, School of Nursing, Ulaanbaatar, MongoliaPCV8 NonePCV9 Mistry of Food and Drug Safety, Osong Health Technology

    Administration Complex, South KoreaPCV10 NonePCV11 NonePCV12 NonePCV13 Medtronic, Minneapolis, MN, USAPCV14 Shiweida Co., Jiling, ChinaPCV15 NonePCV16 NonePCV17 NonePCV18 NonePCV19 NonePCV20 Medtronic, Minneapolis, MN, USAPCV21 NonePCV22 NonePCV23 NonePCV25 St. Jude Medical, Plymouth, MN, USAPCV26 Takeda Pharmaceuticals Taiwan, Ltd., Taipei, TaiwanPCV27 Japan Medical Data Center Co., Ltd., Tokyo, JapanPCV28 Eli-Lilly Company, Indianapolis, IN, USAPCV29 NonePCV30 NonePCV31 NonePCV32 Glaxo, Bangkok, ThailandPCV33 NonePCV34 NonePCV35 Merck Sharp & Dohme, Shanghai, ChinaPCV36 Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Tianjin, ChinaPCV37 Chinese Ministry of Health, Beijing, ChinaPCV38 Pfi zer, Taipei, TaiwanPCV39 NonePCV40 Medtronic Korea, Seoul, South KoreaPCV41 Medtronic, Minneapolis, MN, USAPCV42 Pfi zer Inc., New York, NY, USAPCV43 Merck & Co, Inc., North Wales, PA, USA; Nanjing Medical

    University, Nanjing, ChinaPCV44 NonePCV45 NonePCV46 Eli Lilly and Company, Indianapolis, IN, USAPCV47 Pfi zer, Inc., New York, NY, USAPCV48 Chi-Mei Medical Center, Tainan, TaiwanPCV49 NonePCV50 NonePCV51 NonePCV52 NonePCV53 NonePCV54 Amgen, Thousand Oaks, CA, USAPCV55 NonePCV56 NonePCV57 NonePCV58 NonePDB1 Young Investigator Award, Sichuan University, Chengdu, ChinaPDB2 NonePDB3 NonePDB4 None

    VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 8 1 4 - A 8 1 7 A814

  • A815 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 8 1 4 - A 8 1 7

    REFERENCE CODE

    FINANCIAL SUPPORT

    PDB5 NonePDB6 NonePDB7 Becton, Dickinson and Company, Beijing, ChinaPDB8 NonePDB9 NonePDB10 NonePDB11 MSD China, Beijing, ChinaPDB12 MSD China, Beijing, ChinaPDB13 Novo Nordisk, Kuala Lumpur, MalaysiaPDB14 NonePDB15 Novo Nordisk, Kuala Lumpur, MalaysiaPDB16 NonePDB17 Novo Nordisk, Mexico City, MexicoPDB18 Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, ChinaPDB19 NonePDB20 Japan Medical Data Center Co., Ltd., Tokyo, JapanPDB21 NonePDB22 Department of Health, Sichuan Province, Chengdu, ChinaPDB23 NonePDB24 NonePDB25 NonePDB26 Boffo - Ipsen (Tianjin) Pharmaceutical Co., Ltd., Tianjin, ChinaPDB27 Bristol-Myers Squibb, Shanghai, ChinaPDB28 NonePDB29 Australian National Health and Medical Research Council,

    Canberra, AustraliaPDB30 NonePDB31 Kantar Health, New York, NY, USAPDB32 NonePDB34 NonePDB35 NonePDB37 NonePDB38 NonePDB39 NonePDB40 NonePDB41 NonePDB42 NonePDB43 National Science Foundation, Taipei, TaiwanPDB44 NonePDB45 Chair on adherence to Treatments, Qubec, QC, CanadaPDB46 National Health Insurance Service, Seoul, South KoreaPDB47 BD, Franklin Lakes, NJ, USAPDB48 Ministry of Health, Kuala Lumpur, MalaysiaPGI1 NonePGI2 NonePGI3 NonePGI4 NonePGI5 Roche Diagnostics (Shanghai) Co., Ltd., Shanghai, ChinaPGI6 AstraZeneca, Mississauga, ON, CanadaPHP1 Silpakorn University, NakornPathom Province, ThailandPHP2 NonePHP3 NonePHP4 Aga Khan University, Karachi, PakistanPHP5 Aga Khan University, Karachi, Pakistan; Higher Education

    Commission, Islamabad, PakistanPHP6 National Natural Science Foundation of China, Beijing, ChinaPHP7 National Natural Science Foundation of China, Beijing, ChinaPHP8 Delhi Society for Promotion of Rational Use of Drugs & WHO

    SEARO, New Delhi, IndiaPHP9 NonePHP10 NonePHP11 National Institute of Health Research and Development, Jakarta

    Selatan, IndonesiaPHP12 NonePHP14 NonePHP15 National Natural Science Foundation of China, Beijing, ChinaPHP16 NonePHP17 NonePHP18 NonePHP19 NonePHP20 NonePHP22 NonePHP23 NonePHP24 NonePHP25 NonePHP26 National Institute on Aging, Bethesda, MD, USAPHP28 NonePHP29 NonePHP31 NonePHP32 NonePHP33 Ministry of Health, Kuala Lumpur, Malaysia; United Nation

    Development Programme, Kuala Lumpur, MalaysiaPHP34 NonePHP35 ASCEND Research Network, Austerlia, AustraliaPHP36 None

    REFERENCE CODE

    FINANCIAL SUPPORT

    PHP37 Agency for Integrated Care, Singapore, SingaporePHP38 NonePHP39 NonePHP40 NonePHP41 NonePHP42 Ministry of Health, Singapore, SingaporePHP43 NonePHP44 School of Nursing, Health Science University of Mongolia,

    Ulaanbaatar, MongoliaPHP46 Department of Health, Sichuan Province, Chengdu, ChinaPHP47 NonePHP48 NonePHP49 NonePHP50 NonePHP52 Nursing School, HSUM, Ulaanbaatar, MongoliaPHP53 School of Nursing, Ulaanbaatar, MongoliaPHP54 NonePHP55 NonePHP56 NonePHP57 NonePHP58 Bristol-Myers Squibb, Mulgrave, AustraliaPHP59 NonePHP60 NonePHP61 Lancaster University, Lancaster, UKPHP62 NonePHP63 The Alliance for Health Policy and Systems Research (AHPSR),

    the World Health Organization, Geneva, Switzerland; Shandong University, Jinan, China

    PHP64 NonePHP65 NonePHP66 NonePHP67 NonePHP68 NonePHP70 NonePHP71 NonePHP72 NonePHP73 NonePHP74 NonePHP75 NonePHP76 NonePHP77 NonePHP78 Tehran University of Medical Sciences, Tehran, IranPHP79 China Medical Board, Boston, MA, USAPHP81 NonePHP82 NonePHP83 National Health Insurance Administration, Taipei City, TaiwanPHP84 NonePHP85 NonePHP87 NonePHP88 NonePHP89 NonePHP90 NonePHP91 Johnson & Johnson Medical Asia-Pacifi c, Singapore, SingaporePHP92 NonePHP93 NonePHP94 NonePHP95 Department of Health, Manila, PhilippinesPHP96 NonePHP97 Health Sciences University of Mongolia, School of Nursing,

    Ulaanbaatar, MongoliaPHP98 NonePHP100 School of Nursing, Health Science University of Mongolia,

    Ulaanbaatar, MongoliaPHP101 NonePHP102 NonePHP103 NonePHP104 NonePHP105 NonePHP106 NonePHP107 Ministry of Higher Education, Putrajaya, Malaysia; Universiti

    Kebangsaan Malaysia, Kuala Lumpur, MalaysiaPHP108 NonePHP110 NonePHP111 ICON Clinical Research UK Ltd., London, UKPHP113 NonePIH1 NonePIH2 NonePIH3 NonePIH4 NonePIH5 NonePIH7 NonePIH8 NonePIH10 MSD, China, Shanghai, ChinaPIH11 MSD, China, Shanghai, ChinaPIH12 Ministry of Education and Culture, Jakarta, Indonesia

  • VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 8 1 4 - A 8 1 7 A816

    REFERENCE CODE

    FINANCIAL SUPPORT

    PIH13 NonePIH15 Bristol-Myers Squibb, New York, NY, USAPIH16 Adheris Health, Burlington, MA, USAPIH17 NonePIH18 NonePIH19 NonePIH20 EuroQol Group, Rotterdam, The NetherlandsPIH21 Eli Lilly & Company, Indianapolis, IN, USAPIH22 National Evidence-based healthcare Collaborating Agency, Seoul,

    South Korea; EuroQol group, Rotterdam, The NetherlandsPIH23 Curran Foundation, Sydney, Australia; St Vincents Private

    Hospital, Sydney, Sydney, AustraliaPIH24 Faculty of Pharmacy, Silpakorn University, Nakhon Pathom,

    ThailandPIH25 NonePIH26 NonePIH27 NonePIH28 NonePIH29 NonePIH30 NonePIH31 Chi-Mei medical center, Tainan, Taiwan; Ministry of Health and

    Welfare, Taipei, TaiwanPIH32 NonePIH33 NonePIH34 NonePIH35 NonePIH36 NonePIH37 China Medical Board, Beijing, ChinaPIN1 NonePIN2 NonePIN4 NonePIN5 NonePIN6 MORU, Bangkok, ThailandPIN7 Merck, West Point, PA, USAPIN8 Kantar Health, New York, NY, USAPIN9 Johnson & Johnson Medical, Shanghai, ChinaPIN10 Kantar Health, New York, NY, USAPIN11 School of Nursing, Health Sciensity of Mongolia, Ulaanbaatar,

    MongoliaPIN12 NonePIN14 Eli Lilly China, Shanghai, ChinaPIN15 BMS Foundation, New York, NY, USAPIN16 NonePIN17 NonePIN18 Bristol-Myers Squibb, Shanghai, ChinaPIN19 NonePIN20 GlaxoSmithKline Vaccines, Wavre, BelgiumPIN21 NonePIN22 MSD (Thailand) Ltd., Bangkok, ThailandPIN23 NonePIN24 Ministry of National Education, Republic of Indonesia, Jakarta,

    IndonesiaPIN25 NonePIN26 Department of Health, Manila, Philippines; World Health

    Organization, Geneva, Switzerland; Rockefeller Foundation, NewYork, NY, USA; National Institute for Health and Care Excellence, London, UK

    PIN27 Hoffmann La Roche, New York, NY, USAPIN28 NonePIN29 NonePIN30 NonePIN31 NonePIN32 NonePIN33 NonePIN34 Sanofi -Pasteur MSD, Lyon, FrancePIN35 National AIDS Commission, Jakarta, IndonesiaPMH1 NonePMH2 NonePMH3 NonePMH4 Eli Lilly, Windlesham, UKPMH5 NonePMH6 NonePMH7 NonePMH8 H Lundbeck AS, Valby, DenmarkPMH9 Lundbeck Pte Ltd., Singapore, SingaporePMH10 Janssen Asia Pacifi c, Singapore, SingaporePMH11 NonePMH12 NonePMH13 NonePMH14 NonePMH15 Richter Gedeon Nyrt., Budapest, HungaryPMH16 NonePMH17 Richter Gedeon Nyrt., Budapest, HungaryPMH18 NonePMH19 Lundbeck Pte Ltd., Singapore, SingaporePMH21 Lundbeck Pte Ltd., Singapore, SingaporePMH22 Neopharm, Taejun, South Korea

    REFERENCE CODE

    FINANCIAL SUPPORT

    PMH23 NonePMH25 NonePMH26 NonePMH27 Restore FX, Austin, TX, USAPMH29 Pfi zer Pharmaceuticals Korea Ltd., Seoul, South KoreaPMH30 Universiti Sains Malaysia, Pulau Pinang, MalaysiaPMH32 NonePMH33 Japanese Ministry of Health, Labour and Welfare, Tokyo, JapanPMH34 Hejrat Distribution Company, Tehran, IranPMH35 NonePMH36 Mahasarakham University, Maha Sarakham, ThailandPMS1 Eli Lilly and Company, Indianapolis, IN, USAPMS2 National Natural Science Foundation (81172610), Beijing,

    China; the national science and technology Huimin project (2012GS610101), Beijing, China; International cooperation projects of Shaanxi Province (2012, kw-43), Xian, China; the Fundamental Research Funds for the Central Universities in China(61), Xian, China

    PMS3 NonePMS4 the National Natural Science Foundation of China (No. 81172610),

    Beijing, China; national science and technology Huimin project (2012GS610101), Beijing, China; International cooperation projects of Shaanxi Province (2012, kw-43), Xian, China; science development fund projects of Xian city (GG06176), Xian, China; the Fundamental Research Funds for the Central Universities in China (61), Xian, China

    PMS5 The scientifi c research project of Shaanxi Provincial Department of health: 2012D25, xian, China

    PMS6 NonePMS7 Eli Lilly and Company, Indianapolis, IN, USAPMS8 Pfi zer, Beijing, ChinaPMS9 NonePMS10 NonePMS11 NonePMS12 NonePMS13 NonePMS14 Actelion Pharmaceuticals, Sydney, AustraliaPMS15 NonePMS16 NonePMS17 NonePMS18 Janssen Cilag, Bangkok, ThailandPMS19 Pfi zer, Taipei, TaiwanPMS20 NonePMS21 School of Nursing, Health Science university of Mongolia,

    Ulaanbaatar, MongoliaPMS22 HSUM, School of Nursing, Ulaanbaatar, MongoliaPMS23 Project Supported By Scientifi c Research Fund of Shaanxi

    Provincial Administration of Traditional Chinese Medicine: 13-ZY002, xian, China

    PMS24 NonePMS25 NonePMS26 Johnson & Johnson, Singapore, SingaporePMS27 Johnson & Johnson, Singapore, SingaporePMS28 NonePMS30 NonePMS31 NonePMS32 NonePND1 NonePND2 NonePND3 NonePND4 National Institute for Health Research, Health Technology

    Assessment, Southampton, UKPND5 Kantar Health, Princeton, NJ, USAPND6 Multiple Sclerosis Research Australia, Sydney, AustraliaPND7 Ministry of Health, Labour and Welfare, Tokyo, JapanPND8 NonePND9 NonePND10 NonePND11 Bristol Laboratories Ltd., Luton, UK; Manipal University, Manipal,

    IndiaPRM1 NonePRM2 NonePRM3 NonePRM4 NonePRM5 Ministry of Science and Technology of Peoples Republic of China,

    Beijing, ChinaPRM7 NonePRM8 NonePRM9 Guangzhou Baiyunshan Zhongyi Pharmaceutical Company

    Limited, Guangzhou, ChinaPRM10 Lundbeck Pte Ltd., Singapore, SingaporePRM11 NonePRM12 Eli Lilly and Company, Indianapolis, IN, USAPRM13 Eli Lilly China, Shanghai, ChinaPRM14 NonePRM15 None

  • A817 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 8 1 4 - A 8 1 7

    REFERENCE CODE

    FINANCIAL SUPPORT

    PRM16 Lundbeck Singapore Pte Ltd., Singapore, SingaporePRM17 Merck & Co, Inc., North Wales, PA, USAPRM18 NonePRM19 NonePRM20 Celgene South Korea, Seoul, South KoreaPRM21 AstraZeneca, Molndal, SwedenPRM22 NonePRM23 NonePRM24 NonePRM25 NonePRM26 NonePRM27 National Health and Medical Research Council, Canberra,

    AustraliaPRM28 Ministry of Health, Singapore, Singapore, SingaporePRM29 NonePRM31 NonePRM32 NonePRM33 Scientifi c Foundation Polpharma, Starogard Gdaski, PolandPRM34 NonePRM35 National Pharmaceutical Council, Washington, DC, USAPRM36 NonePRM37 NonePRM38 NonePRM39 NIH, Wisconsin, WI, USAPRM40 NonePRS1 NonePRS2 NonePRS3 Merck &...